Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytoGenix has demonstrated that its synDNA vaccine against HIV has activity in monkeys.
Subscribe to our email newsletter
The study demonstrated that rhesus monkeys injected with a synDNA HIV vaccine mounted a significant cellular immune response. The study involved monkeys treated with a synDNA vaccine targeting two key viral proteins (gag and env) with interleukin-15 as an adjuvant.
“This experiment highlights the potential of the application of synDNA to the field of DNA vaccines as well as the use of DNA therapeutic drugs,” commented Dr Malcolm Skolnick, president and CEO of CytoGenix.
“CytoGenix’s synDNA products present a number of advantages over DNA plasmids produced by bacterial fermentation. The synDNA constructs avoid the use of antibiotic resistance genes and other bacterial sequences, can be rapidly produced and are more cost effective to produce.” commented Dr Yin Chen, chief scientific officer at CytoGenix.
CytoGenix believes that its product has major advantages in developing vaccines for a wide range of applications including pandemic and bioterror threats.